Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease
Titel:
Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease
Auteur:
Addy, Carol Assaid, Chris Hreniuk, David Stroh, Mark Yang Xu, Herring, W. Joseph Ellenbogen, Aaron Jinnah, H.A. Kirby, Louis Leibowitz, Mark T. Stewart, R. Malcolm Tarsy, Daniel Tetrud, James Stoch, S. Aubrey Gottesdiener, Keith Wagner, John